Hypothesis

Aging impairs mitochondrial function in intestinal stem‑cell–derived enterochromaffin (EC) progenitors, reducing ATP‑dependent Piezo1 mechanotransduction and blunting Ca2+ influx needed for 5‑hydroxytryptamine (5‑HT) release. Simultaneously, age‑related shifts in the gut microbiota diminish 5‑hydroxyindole (5‑HI)‑producing bacteria, removing a microbial co‑stimulus that normally synergizes with mechanosensory Ca2+ signals via L‑type calcium channels. The combined deficit pushes EC activity below the threshold required for effective gut motility, creating a feed‑forward loop of dysmotility, small‑intestinal bacterial overgrowth (SIBO), and further microbiota dysregulation.

Mechanistic Rationale

• EC progenitors rely on oxidative phosphorylation to fuel rapid turnover (~16 days) and to sustain high‑energy Ca2+ handling through Piezo1 channels (source).
• Mitochondrial DNA damage and ROS accumulation rise with age, lowering membrane potential and ATP output in epithelial progenitors (established in intestinal aging models).
• Reduced ATP limits Piezo1 channel open probability, decreasing stretch‑induced Ca2+ spikes that trigger vesicular 5‑HT export.
• Microbial 5‑HI acts as an exogenous L‑type Ca2+ channel agonist, raising intracellular Ca2+ and amplifying 5‑HT release when Piezo1 signaling is suboptimal (source).
• Age‑associated loss of 5‑HI‑seeking taxa (e.g., certain Clostridia) thus removes a compensatory boost, pushing total Ca2+ signaling below the exocytosis threshold.
• Slowed motility promotes luminal stasis, favoring SIBO, which further skews tryptophan metabolism away from 5‑HI production (source).

Testable Predictions

1. Mitochondrial rescue: Pharmacologically enhancing EC progenitor mitochondrial function (e.g., with the mitochondria‑targeted peptide SS‑31) will restore Piezo1‑dependent Ca2+ transients and 5‑HT release in aged mice, even without altering the microbiota.
2. Microbial supplementation: Oral administration of a defined 5‑HI‑producing probiotic strain will increase luminal 5‑HI, rescue Ca2+ signaling in aged EC cells, and improve motility only when mitochondrial function is at least partially intact.
3. Combined deficiency: Aged mice with both mitochondrial impairment (via EC‑specific Twinkle helicase knockout) and microbiota depletion (antibiotic cocktail) will show the most severe motility defect, which is not rescued by either intervention alone.

Experimental Approach

• Mouse models: Young (3 mo) and aged (24 mo) C57BL/6 mice; generate EC‑ progenitor‑specific Twinkle^fl/fl;Vil‑CreERT2 line to induce mitochondrial DNA replication stress.
• Interventions: (a) SS‑31 (3 mg/kg i.p. daily, 2 weeks); (b) oral gavage of a 5‑HI‑secreting Escherichia coli Nissle strain engineered to overexpress tryptophan indole‑lyase; (c) broad‑spectrum antibiotics to deplete microbiota.
• Readouts:
  • Isolated crypts: measure mitochondrial membrane potential (TMRM fluorescence) and ATP levels.
  • Calcium imaging of EC progenitors in intestinal organoids using Piezo1 stretch stimulus and 5‑HI application (Fluo‑4 AM).
  • 5‑HT release quantified by ELISA from basolateral media.
  • In vivo colonic transit time via carmine red assay.
  • Microbiota 5‑HI quantification by LC‑MS; 16S rRNA sequencing to confirm strain engraftment.

Potential Outcomes and Falsification

• Support: SS‑31 normalizes mitochondrial ATP, rescues Piezo1 Ca2+ spikes, and increases 5‑HT release in aged ECs; motility improves despite unchanged microbiota. 5‑HI probiotic adds further benefit only when mitochondrial function is not severely compromised.
• Refutation: If mitochondrial enhancement fails to improve Ca2+ signaling or 5‑HT release in aged ECs, or if 5‑HI probiotic restores motility in mice with severe mitochondrial defect, the hypothesis would be weakened, indicating that mitochondrial dysfunction is not the primary limiter or that other pathways dominate.

By linking progenitor bioenergetics, mechanosensing, and microbial metabolite signaling, this hypothesis offers a concrete, falsifiable framework for age‑related gut dysmotility and points to combinatorial therapies targeting both host cell metabolism and microbiota composition.